Yale Cancer Center
Clinical research site in New Haven, Connecticut · 333 CEDAR STREET, DEPARTMENT OF PEDIATRICS , 2073 LMP, NEW HAVEN, CT 06520-8064 · (203) 785-4640
Part of Yale University
As of September 2026, 69 paid clinical trials are recruiting at Yale Cancer Center in New Haven, Connecticut. Active studies at this site cover conditions such as Advanced Solid Tumor, Advanced Solid Tumors and NSCLC. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Yale Cancer Center (69)
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
A Study of PHST001 in Advanced Solid Tumors
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
XTX301 in Patients With Advanced Solid Tumors
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
QTX3034 in Patients With KRAS G12D Mutation
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Showing the 40 most relevant of 69 recruiting trials at this site. Browse all with filters →
Get new-trial alerts for Yale Cancer Center
We'll email you whenever a new clinical trial starts recruiting at this research site in New Haven, CT. Unsubscribe anytime.
More research sites in New Haven
- Yale University (246 trials)
- Yale New Haven Hospital (63 trials)
- Yale University School of Medicine (59 trials)
- Yale School of Medicine (41 trials)
- Smilow Cancer Center/Yale-New Haven Hospital (20 trials)
- Yale (12 trials)
- Yale-New Haven Hospital (12 trials)
- Connecticut Mental Health Center (11 trials)
- GSK Investigational Site (8 trials)
- Smilow Cancer Hospital at Yale New Haven (8 trials)
Is this your research site?
This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.
Explore more
Paid clinical trials in New Haven, CT · Connecticut clinical trials